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‘‘It takes all the running you
can do, to keep in the same
place. If you want to get some-
where else, you must run at
least twice as fast as that!’’
Lewis Carroll’s
Through the Looking-Glass [1]
Many neglected tropical diseases
(NTDs) began millions of years ago as
enzoonotic diseases of wild animals that
subsequently infected humans, leading in
many cases to anthropozoonoses [2].
Because of their impoverished circum-
stances, most humans infected with NTD
agents have few choices but to face daily
the intense selective pressures associated
with high levels of exposure and transmis-
sion that often flourish in these impover-
ished settings [3]. In this dynamic and
relentless evolutionary battle, animal res-
ervoirs, vectors, microbes causing NTDs,
and humans are constantly adapting
through what it is known as the ‘‘Red
Queen Effect’’ from Lewis Carroll’s Red
Queen character [4,5]. Typically, the
battlegrounds of these molecular and
ecological clashes are located in the
poorest regions of developing countries
where they mostly affect the world’s most
vulnerable populations [3].
In Latin America, Chagas disease (CD),
caused by infection with Trypanosoma cruzi,
is a prime example of this co-evolutionary
process in which parasites and mammalian
reservoirs (including humans) are engaged
in a dynamic race of ecological adaptation
and counter-adaptation [6]. In the search
for improved sources of income, agricul-
ture, livestock rearing, and other socioeco-
nomic activities, human populations began
migrating into the natural wild habitats
where T. cruzi infection was enzootic [2].
Ultimately, poverty, poor housing and
sub-standard living conditions, deforesta-
tion, and other ecological factors promot-
ed an adaptation of triatomine vectors to
both humans and domestic animals, with
increased efficiencies of the wild, domestic,
and peridomestic cycles of T. cruzi trans-
mission (Figure 1) [2,7–8]. Once humans
became infected and acted as a reservoir
for the infection, other forms of transmis-
sion also evolved through blood transfu-
sion, congenital transmission, and organ
transplantation. In some settings, oral
transmission through contaminated food
is now considered an important mode of
transmission [3,8].
We are about to celebrate the 100th
anniversary of the discovery of T. cruzi and
its link to CD. The cycle of transmission
(vector, reservoir, and infectious agent)
and the clinical manifestations of the
disease were elegantly described by Carlos
Chagas (1879–1934) during the first de-
cade of the 20th century. Oswaldo Cruz,
his mentor, had set the stage for these
achievements by creating a research
institution bearing his name in Brazil
(Instituto Oswaldo Cruz – FIOCRUZ)
[7,9–10]. For his multiple achievements,
Carlos Chagas received several awards
and international distinctions and became
the Director of the Institute in 1917 (after
Oswaldo Cruz’s death), holding this title
until his own death in 1934. It was
Salvador Mazza in Argentina who
brought again Chagas’s achievements into
the international scope by identifying cases
of CD in the Argentine Chaco region [9].
In subsequent years, a few dedicated
clinicians in Latin America expanded the
initial clinical descriptions of the disease
made by Carlos Chagas. During this
period, the French parasitologist Emile
Brumpt is often credited with developing
important xenodiagnostic techniques [10].
Due to these landmark discoveries, it is
now recognized that the natural history of
CD has three clinical stages [2,3]. An initial
acute stage representing the entry of the
parasite and invasion of the bloodstream in
which most patients are asymptomatic is
followed by an indeterminate stage that is
defined by the absence of symptoms and
clinical findings in patients with a positive
serology for T. cruzi. The indeterminate
stage (also called early chronic) is followed
by chronic complications in approximately
20%–30% of patients many years after the
initial infection. Serious cardiac (e.g., car-
diomyopathy) and gastrointestinal (e.g.,
megaesophagus and megacolon) morbidi-
ties are the most frequent manifestations of
chronicCDandthemaincauseofdisability
and death [2].
During the early 1980s, the prevalence
of CD was first reliably estimated and the
full social and economic implications of
this condition were revealed. It was
determined that there were 18 million
cases in 21 endemic countries with 100
million people at risk of infection [9]. In
1993, CD ranked as the most important
tropical disease in Latin America in terms
of burden of disease [9]. Subsequently,
through political commitment and effec-
tive public health interventions, some
progress was achieved in reducing the
incidence and prevalence of CD, particu-
larly in the southernmost countries of
Latin America. The major approaches to
control CD have included improved case
management and vector control programs,
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through regional programs and blood
bank screening [2,6,7–9]. To date, the
major regional initiatives combining some
of these interventions have included the
Southern Cone Initiative (INCOSUR)
created in 1991, followed by the Andean
Initiative in 1997 (ACI-IPA), and the
Central America and Mexico Initiative
(IPCA-MEXICO) and Amazon Initiative
(AMCHA) in 2004. As a result of these
programs and according to the most
recent estimates, the number of people
currently infected with CD has been
reduced to approximately 7.6 million, with
75 million people still living at risk of
infection [11].
In spite of these substantial achieve-
ments, many challenges remain ahead for
the control and ultimately the elimination
of CD. Together with the intestinal
helminth infections, CD is responsible for
the highest estimated disease burden due
to infectious diseases in Latin America [6].
In addition, the huge impact of CD on
worker productivity and maternal child
health continues to contribute to under-
development [3,6]. Some of the successes
in the control of the disease are in
jeopardy. For instance, in the Southern
Cone, where domestic transmission has
been nearly eliminated through vector
control of Triatoma infestans, there are
concerns that the vacant niches will be
eventually occupied by other triatomine
vectors [6,8]. In other parts of Latin
America, poor governance and politically
motivated human rights violations have
facilitated the emergence and geographic
spread of CD [12]. There is even strong
evidence for autochthonous transmission
within the borders of the United States,
especially in the southern states [13].
Additionally, due to regional and global
migration caused by economic hardship,
the geographic reach of CD has expanded
from rural to urban areas in endemic
countries as well as in non-endemic
countries, a phenomenon sometimes re-
ferred to as the globalization of CD
(Figure 2) [14].
Current prevention strategies are not
enough to control the burden of disease
associated with CD. The diagnosis and
treatment for every affected individual
with CD are moral imperatives and
represent a human rights priority [12].
Health care access for diagnosis and
treatment is limited in impoverished areas
in highly endemic settings [3]. The major
antiparasitic drugs used are expensive or
toxic, sometimes unavailable, and are not
sufficiently effective to treat the chronic
forms of the disease [6,8]. In this and an
upcoming issue of PLoS Neglected Tropical
Diseases, a series of articles coordinated by
Me ´dicins Sans Frontie ´res (MSF) and
Drugs for Neglected Disease Initiative
(DNDi) address some of the challenges
Figure 1. The cycle of transmission of Trypanosoma cruzi, the causative agent of Chagas disease to humans. From [3].
doi:10.1371/journal.pntd.0000470.g001
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these two organizations to ameliorate the
medical impact of CD in highly affected
areas [15,16].
In the first report of the series, MSF
workers in the field demonstrate from an
operational perspective the feasibility of
implementing CD diagnosis and treatment
protocols in highly affected populations in
Honduras, Guatemala, and Bolivia [15].
Through their important contributions in
the diagnosis and treatment of CD, MSF
has proven the importance of establishing
case management protocols that include
information, education, and communica-
tion at the community and family level, as
well as protocols for health staff training
with regard to screening, diagnosis, and
treatment of CD. This study also confirms
the need for better drugs with improved
safety profiles, the urgent need for the
development of formulations for pediatric
cases, and the need for better serological
or molecular tests of cure within case
management protocols [15]. In another
article in the series, Riberio et al. present
the current and future state of CD drug
development by describing current re-
search and development funding, products
in the development pipeline, and products
undergoing clinical evaluation [16].
In the coming decade, we anticipate
multiple challenges to control or eliminate
the medical and public health impact of
CD. They include the following:
N scaling of integrated control programs
throughout all affected countries by
blood bank screening, residual insecti-
cide treatment of vector-infested
homes, health promotion and educa-
tion, and community surveillance of
house re-infestation in endemic set-
tings [6];
N improving access to high-quality
health care for diagnosis and treat-
ment of CD and its cardiac, gastroin-
testinal, and neurological complica-
tions in endemic settings [15];
N expanding screening, diagnosis, and
treatment protocols of CD in non-
endemic settings receiving large num-
bers of migrants from areas of ende-
micity in Latin America [13,14];
N expanding screening and treatment to
prevent congenital CD transmission in
endemic settings [6];
N developing and testing more effica-
cious and safer drugs for the acute,
indeterminate, and chronic forms of
the disease [16]; and
N further defining the epidemiologic and
clinical manifestations of CD co-infec-
tion or reactivation among patients
with HIV/AIDS and other immuno-
Figure 2. Globalization of Chagas disease from endemic to non-endemic settings. Reprinted with permission from Memo ´rias do Instituto
Oswaldo Cruz [14].
doi:10.1371/journal.pntd.0000470.g002
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and non-endemic settings [17].
In order to address these challenges,
and in support of the existing MSF and
DNDi initiatives, the Global Network for
Neglected Tropical Diseases of the Sabin
Vaccine Institute is working in collabora-
tion with the Inter-American Develop-
ment Bank and the Pan American Health
Organization to support large-scale pro-
grams for the control of CD and other
NTDs in the Latin American region.
Simultaneously, several product develop-
ment partnerships, including DNDi and
the Sandler Center at the University of
California San Francisco, as well as a new
NTD research and development initiative
of the Brazilian Ministry of Health, are
working to develop new and improved
control tools for CD. Once again, FIO-
CRUZ will be at the forefront of many of
these new endeavors.
In summary, there are ongoing social
and biological evolutionary races sur-
rounding CD transmission and control
on a global scale. We must run at least
twice as fast to increase our efforts to
control this poverty-promoting disease. By
controlling CD and other NTDs in Latin
America, as demonstrated by the pro-
grams and strategies of MSF and DNDi,
the most vulnerable populations in this
region may be in a better position to
achieve the Millennium Development
Goals.
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